Clinical Trial Update: A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

View source ↗

Summary

A single-arm expanded-access study of zanubrutinib in Waldenström macroglobulinemia is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Waldenström Macroglobulinemia | Status: NO_LONGER_AVAILABLE